RESUMO
OBJECTIVES: The exposure of neurons to an excessive excitatory stimulation induces the alteration of the normal neuronal function. Mood disorders are among the first signs of alterations in the central nervous system function. Magnolia officinalis bark extract has been extensively used in the traditional medicine systems of several countries, showing several pharmacological activities. Honokiol, the main constituent of M. officinalis, is a GABA modulator and a CB1 agonist, which is deeply investigated for its role in modulating mood disorders. METHODS: Thus, we evaluated the possible neuroprotective effect of a standardized M. officinalis bark extract (MOE), enriched in honokiol, and its effect on animal mood behavioural tests and in an in vitro model of excitotoxicity. KEY FINDINGS: MOE showed neuroprotective effect using SH-SY5Y cells, by normalizing brain-derived neurotrophic factor release. Then, we tested the effect of MOE in different behavioural tests evaluating anxiety and depression and we observed a selective anxiolytic-like effect. Finally, we confirmed the involvement of CB1 in the final effect of MOE by the co-administration of the CB1 antagonist, AM251. CONCLUSION: These results suggest that MOE could be considered an effective and safe anxiolytic candidate with neuroprotective activity.
Assuntos
Ansiolíticos/farmacologia , Ansiedade/metabolismo , Compostos de Bifenilo/farmacologia , Lignanas/farmacologia , Magnolia/química , Fármacos Neuroprotetores/farmacologia , Extratos Vegetais/farmacologia , Receptor CB1 de Canabinoide/agonistas , Animais , Ansiolíticos/uso terapêutico , Ansiedade/tratamento farmacológico , Transtornos de Ansiedade/tratamento farmacológico , Transtornos de Ansiedade/metabolismo , Comportamento Animal/efeitos dos fármacos , Compostos de Bifenilo/uso terapêutico , Encéfalo , Fator Neurotrófico Derivado do Encéfalo/metabolismo , Moduladores GABAérgicos/farmacologia , Moduladores GABAérgicos/uso terapêutico , Humanos , Lignanas/uso terapêutico , Masculino , Camundongos , Fármacos Neuroprotetores/uso terapêutico , Fitoterapia , Casca de Planta/química , Extratos Vegetais/uso terapêutico , Receptor CB1 de Canabinoide/antagonistas & inibidoresRESUMO
BACKGROUND: Previous studies have shown that seizures can cause cognitive disorders. On the other hand, the Curcuma zedoaria (CZ) has beneficial effects on the nervous system. However, there is little information on the possible effects of the CZ extract on seizures. The aim of this study was to investigate the possible effects of CZ extract on cognitive impairment and oxidative stress induced by epilepsy in rats. METHODS: Rats were randomly divided into different groups. In all rats (except the sham group), kindling was performed by intraperitoneal injection of pentylenetetrazol (PTZ) at a dose of 35 mg/kg every 48 h for 14 days. Positive group received 2 mg/kg diazepam + PTZ; treatment groups received 100, 200 or 400 mg/kg CZ extract + PTZ; and one group received 0.5 mg/kg flumazenil and CZ extract + PTZ. Shuttle box and Morris Water Maze tests were used to measure memory and learning. On the last day of treatments PTZ injection was at dose of 60 mg/kg, tonic seizure threshold and mortality rate were recorded in each group. After deep anesthesia, blood was drawn from the rats' hearts and the hippocampus of all rats was removed. RESULTS: Statistical analysis of the data showed that the CZ extract significantly increased the tonic seizure threshold and reduced the pentylenetetrazol-induced mortality and the extract dose of 400 mg/kg was selected as the most effective dose compared to the other doses. It was also found that flumazenil (a GABAA receptor antagonist) reduced the tonic seizure threshold compared to the effective dose of the extract. The results of shuttle box and Morris water maze behavioral tests showed that memory and learning decreased in the negative control group and the CZ extract treatment improved memory and learning in rats. The CZ extract also increased antioxidant capacity, decreased MDA and NO in the brain and serum of pre-treated groups in compared to the negative control group. CONCLUSION: It is concluded that the CZ extract has beneficial effects on learning and memory impairment in PTZ-induced epilepsy model, which has been associated with antioxidant effects in the brain or possibly exerts its effects through the GABAergic system.
Assuntos
Química Encefálica/efeitos dos fármacos , Curcuma/química , Deficiências da Aprendizagem/tratamento farmacológico , Transtornos da Memória/tratamento farmacológico , Estresse Oxidativo/efeitos dos fármacos , Extratos Vegetais/uso terapêutico , Convulsões/psicologia , Animais , Anticonvulsivantes/uso terapêutico , Antioxidantes/farmacologia , Convulsivantes , Flumazenil/uso terapêutico , Moduladores GABAérgicos/uso terapêutico , Deficiências da Aprendizagem/psicologia , Masculino , Malondialdeído/metabolismo , Aprendizagem em Labirinto , Transtornos da Memória/psicologia , Óxido Nítrico/metabolismo , Pentilenotetrazol , Ratos , Ratos Wistar , Convulsões/induzido quimicamenteRESUMO
AIM: Rapid eye movement sleep behaviour disorder (RBD) is characterized by abnormal behaviours accordant with nightmares during rapid eye movement sleep and is considered a prodromal marker of dementia with Lewy body. Most common in the elderly population, RBD is generally treated with clonazepam (CZP), a long-term acting benzodiazepine antiepileptic. As such, alternative drugs for RBD are urgently needed to minimize the adverse effects peculiar to benzodiazepines. The efficacy of yokukansan (YKS), a traditional Japanese herbal medicine, on RBD was initially reported by Shinno et al. in 2008. However, no study has compared YKS with CZP. Therefore, this study aimed to clarify the possibility of using YKS as an alternative to CZP. METHODS: This was a retrospective cohort study conducted at Jikei University Affiliated Hospital. The subjects were selected from 36 outpatients who had been diagnosed with RBD based on the International Classification of Sleep Disorders, third edition. Of the 23 who met the inclusion criteria but not the exclusion criteria, 11 were treated with YKS monotherapy, and 12 were treated with CZP monotherapy. The primary outcome was the total score on the Japanese version of the Rapid Eye Movement Sleep Behaviour Disorder Questionnaire (RBDQ-JP), and the secondary outcomes were the scores from the eight-item Short-Form Health Survey and factors 1 and 2 of the RBDQ-JP. RESULTS: The mean total RBDQ-JP score significantly improved from 52.5 to 21.7 (P = 0.002) after treatment with YKS (mean dosage: 3.0 g/day), which was similar to the change after CZP treatment (from 43.8 to 21.3). On RBDQ-JP factor 1 (dream content), the mean score on five of six items significantly improved after treatment with YKS. There was no significant change in Short-Form Health Survey scores after treatment with either drug. Potassium concentrations were within the normal range in patients treated with YKS. CONCLUSIONS: The present results suggest that a small amount of YKS may be an alternative to CZP for RBD, without remarkable adverse events. Further study is needed to prospectively clarify the efficacy and safety of YKS in more detail.
Assuntos
Anticonvulsivantes/uso terapêutico , Clonazepam/uso terapêutico , Medicamentos de Ervas Chinesas/uso terapêutico , Moduladores GABAérgicos/uso terapêutico , Transtorno do Comportamento do Sono REM/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Transtorno do Comportamento do Sono REM/diagnóstico , Estudos Retrospectivos , Resultado do TratamentoRESUMO
Pharmacologic management of hepatic encephalopathy includes a broad range of therapies. This article covers the specific mainstays of therapies, such as antimicrobials and laxatives, with an established evidence base. This article also covers newer modalities of therapies, such as fecal microbiota transplant, probiotics, bioartificial support systems, small molecular therapies such as l-ornithine l-aspartate, branched chain amino acids, l-carnitine, zinc, and other forms of therapy currently under review.
Assuntos
Antibacterianos/uso terapêutico , Encefalopatia Hepática/terapia , Laxantes/uso terapêutico , Rifaximina/uso terapêutico , Acarbose/uso terapêutico , Aminoácidos de Cadeia Ramificada/uso terapêutico , Dipeptídeos/uso terapêutico , Transplante de Microbiota Fecal , Flumazenil/uso terapêutico , Moduladores GABAérgicos/uso terapêutico , Glicerol/análogos & derivados , Glicerol/uso terapêutico , Inibidores de Glicosídeo Hidrolases/uso terapêutico , Humanos , Lactulose/uso terapêutico , Fenilbutiratos/uso terapêutico , Probióticos/uso terapêuticoRESUMO
BACKGROUND: Insomnia is the most common sleep disorder. The present study was undertaken to evaluate the sedative-hypnotic potential of hydroalcoholic extract (HAE) of Cuscuta epithymum and its fractions. METHOD: HAE and its fractions including: water fraction (WF), ethyl acetate fraction (EAF) and n-hexan fraction (NHF) were i.p administered to male mice and 30 min later pentobarbital (30 mg/kg, i.p.) was injected to induce sleep. Then the latent period and continuous sleeping time were recorded. Besides, 30 mins after administration of HAE motor coordination (rota-rod test) were assessed. Additionally, LD50 of HAE was determined and the possible neurotoxicity of the extract was tested on neural PC12 cells. RESULTS: The HAE and NHF decreased the latency of sleep and significantly increased the duration of sleep induced by pentobarbital. These effects of C. epithymum were reversed by flumazenil. HAE did not affect the animals' performance on the rotarod test. The LD50 value for HAE was found to be 4.8 g/kg. HAE and its fractions had no toxicity effect on the viability of PC12-cell line. CONCLUSION: The results of the present study indicate that the HAE and NHF have significant sedativehypnotic effects in mice without major toxic effect and that the benzodiazepine receptors are involved in the sedative-hypnotic effects of this plant.
Assuntos
Cuscuta/química , Moduladores GABAérgicos/farmacologia , Pentobarbital/farmacologia , Extratos Vegetais/farmacologia , Distúrbios do Início e da Manutenção do Sono/tratamento farmacológico , Acetatos/química , Animais , Linhagem Celular , Modelos Animais de Doenças , Sinergismo Farmacológico , Moduladores GABAérgicos/isolamento & purificação , Moduladores GABAérgicos/uso terapêutico , Neurônios GABAérgicos/efeitos dos fármacos , Neurônios GABAérgicos/metabolismo , Hexanos/química , Humanos , Masculino , Camundongos , Pentobarbital/uso terapêutico , Extratos Vegetais/isolamento & purificação , Extratos Vegetais/uso terapêutico , Ratos , Receptores de GABA-A/metabolismo , Solventes/química , Água/químicaRESUMO
Essential tremor is the most common cause of tremor involving upper limbs, head and voice. The first line of treatment for limb tremor is pharmacotherapy with propranolol or primidone. However, these two drugs reduce the tremor severity by only half. In medication refractory and functionally disabling tremor, alternative forms of therapy need to be considered. Botulinum toxin injections are likely efficacious for limb, voice and head tremor but are associated with side effects. Surgical interventions include deep brain stimulation; magnetic resonance-guided focused ultrasound and thalamotomy for unilateral and deep brain stimulation for bilateral procedures. Recent consensus classification for essential tremor has included a new subgroup, 'Essential tremor plus', who have associated subtle neurological 'soft signs', such as dystonic posturing of limbs and may require a different treatment approach. In this review, we have addressed the current management of essential tremor with regard to different anatomical locations of tremor as well as different modalities of treatment.
Assuntos
Inibidores da Liberação da Acetilcolina/uso terapêutico , Antagonistas Adrenérgicos beta/uso terapêutico , Estimulação Encefálica Profunda/métodos , Tremor Essencial/terapia , Moduladores GABAérgicos/uso terapêutico , Ablação por Ultrassom Focalizado de Alta Intensidade/métodos , Tálamo/cirurgia , Toxinas Botulínicas/uso terapêutico , Tremor Essencial/fisiopatologia , Humanos , Imageamento por Ressonância Magnética , Primidona/uso terapêutico , Propranolol/uso terapêutico , Cirurgia Assistida por Computador , Estimulação Magnética TranscranianaRESUMO
BACKGROUND: Altered neurotransmission of γ-aminobutyric acid (GABA) has been implicated in the pathogenesis of depression. Whether SAGE-217, an oral, positive allosteric modulator of GABA type A receptors, is effective and safe for the treatment of major depressive disorder is unknown. METHODS: In this double-blind, phase 2 trial, we enrolled patients with major depression and randomly assigned them in a 1:1 ratio to receive 30 mg of SAGE-217 or placebo once daily. The primary end point was the change from baseline to day 15 in the score on the 17-item Hamilton Depression Rating Scale (HAM-D; scores range from 0 to 52, with higher scores indicating more severe depression). Secondary efficacy end points, which were assessed on days 2 through 8 and on days 15, 21, 28, 35, and 42, included changes from baseline in scores on additional depression and anxiety scales, a reduction from baseline of more than 50% in the HAM-D score, a HAM-D score of 7 or lower, and a Clinical Global Impression of Improvement score of 1 (very much improved) or 2 (much improved) (on a scale of 1 to 7, with a score of 7 indicating that symptoms are very much worse). RESULTS: A total of 89 patients underwent randomization: 45 patients were assigned to the SAGE-217 group, and 44 to the placebo group. The mean baseline HAM-D score was 25.2 in the SAGE-217 group and 25.7 in the placebo group. The least-squares mean (±SE) change in the HAM-D score from baseline to day 15 was -17.4±1.3 points in the SAGE-217 group and -10.3±1.3 points in the placebo group (least-squares mean difference in change, -7.0 points; 95% confidence interval, -10.2 to -3.9; P<0.001). The differences in secondary end points were generally in the same direction as those of the primary end point. There were no serious adverse events. The most common adverse events in the SAGE-217 group were headache, dizziness, nausea, and somnolence. CONCLUSIONS: Administration of SAGE-217 daily for 14 days resulted in a reduction in depressive symptoms at day 15. Adverse events were more common in the SAGE-217 group than in the placebo group. Further trials are needed to determine the durability and safety of SAGE-217 in major depressive disorder and to compare SAGE-217 with available treatments. (Funded by Sage Therapeutics; ClinicalTrials.gov number, NCT03000530.).
Assuntos
Antidepressivos/uso terapêutico , Transtorno Depressivo Maior/tratamento farmacológico , Moduladores GABAérgicos/uso terapêutico , Pregnanos/uso terapêutico , Pirazóis/uso terapêutico , Receptores de GABA-A/metabolismo , Administração Oral , Adulto , Regulação Alostérica , Antidepressivos/efeitos adversos , Transtorno Depressivo Maior/classificação , Tontura/induzido quimicamente , Método Duplo-Cego , Feminino , Moduladores GABAérgicos/efeitos adversos , Humanos , Análise dos Mínimos Quadrados , Masculino , Pessoa de Meia-Idade , Náusea/induzido quimicamente , Pregnanos/efeitos adversos , Escalas de Graduação Psiquiátrica , Pirazóis/efeitos adversosRESUMO
Postpartum depression is one of the most common complications of childbirth. Untreated postpartum depression can have substantial adverse effects on the well-being of the mother and child, negatively impacting child cognitive, behavioral, and emotional development with lasting consequences. There are a number of therapeutic interventions for postpartum depression including pharmacotherapy, psychotherapy, neuromodulation, and hormonal therapy among others, most of which have been adapted from the treatment of major depressive disorder outside of the peripartum period. Current evidence of antidepressant treatment for postpartum depression is limited by the small number of randomized clinical trials, underpowered samples, and the lack of long-term follow-up. The peripartum period is characterized by rapid and significant physiological change in plasma levels of endocrine hormones, peptides, and neuroactive steroids. Evidence supporting the role of neuroactive steroids and γ-aminobutyric acid (GABA) in the pathophysiology of postpartum depression led to the investigation of synthetic neuroactive steroids and their analogs as potential treatment for postpartum depression. Brexanolone, a soluble proprietary intravenous preparation of synthetic allopregnanolone, has been developed. A recent series of open-label and placebo-controlled randomized clinical trials of brexanolone in postpartum depression demonstrated a rapid reduction in depressive symptoms, and has led to the submission for regulatory approval to the US Food and Drug Administration (decision due in March 2019). SAGE-217, an allopregnanolone analog, with oral bioavailability, was recently tested in a randomized, double-blind, placebo-controlled phase III study in severe postpartum depression, with reportedly positive results. Finally, a 3ß-methylated synthetic analog of allopregnanolone, ganaxolone, is being tested in both intravenous and oral forms, in randomized, double-blind, placebo-controlled phase II studies in severe postpartum depression.
Assuntos
Depressão Pós-Parto/tratamento farmacológico , Desenvolvimento de Medicamentos , Moduladores GABAérgicos/uso terapêutico , Neuroesteroides/uso terapêutico , Pregnanos/uso terapêutico , Pregnanolona/uso terapêutico , Pirazóis/uso terapêutico , beta-Ciclodextrinas/uso terapêutico , Animais , Depressão Pós-Parto/epidemiologia , Depressão Pós-Parto/metabolismo , Combinação de Medicamentos , Feminino , Moduladores GABAérgicos/administração & dosagem , Moduladores GABAérgicos/efeitos adversos , Humanos , Neuroesteroides/administração & dosagem , Neuroesteroides/efeitos adversos , Pregnanos/administração & dosagem , Pregnanos/efeitos adversos , Pregnanolona/administração & dosagem , Pregnanolona/efeitos adversos , Pirazóis/administração & dosagem , Pirazóis/efeitos adversos , Ensaios Clínicos Controlados Aleatórios como Assunto , Estados Unidos , United States Food and Drug Administration , beta-Ciclodextrinas/administração & dosagem , beta-Ciclodextrinas/efeitos adversosAssuntos
Transtorno Obsessivo-Compulsivo/complicações , Transtorno Obsessivo-Compulsivo/terapia , Transtornos Relacionados ao Uso de Substâncias/complicações , Transtornos Relacionados ao Uso de Substâncias/terapia , Agonistas de Receptores Adrenérgicos alfa 2/uso terapêutico , Clonazepam/uso terapêutico , Clonidina/uso terapêutico , Terapia Combinada/métodos , Fluoxetina/uso terapêutico , Moduladores GABAérgicos/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Naltrexona/uso terapêutico , Antagonistas de Entorpecentes/uso terapêutico , Terapia de Relaxamento/métodos , Inibidores Seletivos de Recaptação de Serotonina/uso terapêuticoAssuntos
Meditação/psicologia , Transtornos Psicóticos/etiologia , Adulto , Antipsicóticos/uso terapêutico , Moduladores GABAérgicos/uso terapêutico , Haloperidol/uso terapêutico , Humanos , Lorazepam/uso terapêutico , Masculino , Prometazina/uso terapêutico , Transtornos Psicóticos/tratamento farmacológico , Risperidona/uso terapêuticoRESUMO
Burning mouth syndrome (BMS) is a chronic oral pain syndrome that primarily affects peri- and postmenopausal women. It is characterized by oral mucosal burning and may be associated with dysgeusia, paresthesia, dysesthesia, and xerostomia. The etiology of the disease process is unknown, but is thought to be neuropathic in origin. The goal of this systematic review was to assess the efficacy of the various treatments for BMS. Literature searches were conducted through PubMed, Web of Science, and Cochrane Library databases, which identified 22 randomized controlled trials. Eight studies examined alpha-lipoic acid (ALA), three clonazepam, three psychotherapy, and two capsaicin, which all showed modest evidence of potentially decreasing pain/burning. Gabapentin was seen in one study to work alone and synergistically with ALA. Other treatments included vitamins, benzydamine hydrochloride, bupivacaine, Catuama, olive oil, trazodone, urea, and Hypericum perforatum. Of these other treatments, Catuama and bupivacaine were the only ones with significant positive results in symptom improvement. ALA, topical clonazepam, gabapentin, and psychotherapy may provide modest relief of pain in BMS. Gabapentin may also boost the effect of ALA. Capsaicin is limited by its side effects. Catuama showed potential for benefit. Future studies with standardized methodology and outcomes containing more patients are needed.
Assuntos
Antioxidantes/uso terapêutico , Síndrome da Ardência Bucal/tratamento farmacológico , Clonazepam/uso terapêutico , Moduladores GABAérgicos/uso terapêutico , Ácido Tióctico/uso terapêutico , Aminas/uso terapêutico , Analgésicos/uso terapêutico , Síndrome da Ardência Bucal/terapia , Capsaicina/uso terapêutico , Ácidos Cicloexanocarboxílicos/uso terapêutico , Gabapentina , Humanos , Medição da Dor , Psicoterapia , Fármacos do Sistema Sensorial/uso terapêutico , Ácido gama-Aminobutírico/uso terapêuticoAssuntos
Consumo Excessivo de Bebidas Alcoólicas/complicações , Comportamento Ritualístico , Comportamento Compulsivo/complicações , Magia/psicologia , Transtorno Obsessivo-Compulsivo/complicações , Adulto , Antipsicóticos/uso terapêutico , Consumo Excessivo de Bebidas Alcoólicas/psicologia , Consumo Excessivo de Bebidas Alcoólicas/terapia , Clonazepam/uso terapêutico , Terapia Cognitivo-Comportamental , Comportamento Compulsivo/psicologia , Comportamento Compulsivo/terapia , Fluvoxamina/uso terapêutico , Moduladores GABAérgicos/uso terapêutico , Humanos , Masculino , Transtorno Obsessivo-Compulsivo/psicologia , Transtorno Obsessivo-Compulsivo/terapia , Risperidona/uso terapêutico , Inibidores Seletivos de Recaptação de Serotonina/uso terapêuticoRESUMO
The broad use of atypical antipsychotics was expected to dramatically reduce the prevalence and incidence of tardive dyskinesia (TD), but data show that TD remains an important challenge due the persistent nature of its symptoms and resistance to numerous treatment modalities, including antipsychotic discontinuation. Recent insights on genetic risk factors and new concepts surrounding pathophysiology have spurred interest in the possibility of targeted treatment for TD. As will be reviewed in this article, the number of evidence-based strategies for TD treatment is small: only clonazepam, amantadine, ginkgo biloba extract, and the vesicular monoamine transporter 2 (VMAT2) inhibitor tetrabenazine have compelling data. Using new insights into the metabolism of tetrabenazine and the properties of its active metabolites, 2 modifications of tetrabenazine have been synthesized to improve the kinetic profile, and are currently involved in double-blind placebo controlled studies aimed at U.S. Food and Drug Administration (FDA) regulatory approval. The possible availability of these new agents, deuterated tetrabenazine and valbenazine, significantly widens the range of treatment choices for patients with TD. For clinicians with patients at risk for TD due to dopamine antagonist exposure, experience has shown that the problem of TD will be an ongoing issue in modern psychiatry, and that an appreciation of new developments in the pathophysiology of, risk factors for, and treatment of TD is crucial to managing this condition.
Assuntos
Antipsicóticos/efeitos adversos , Antagonistas de Dopamina/efeitos adversos , Discinesia Tardia/induzido quimicamente , Inibidores da Captação Adrenérgica/uso terapêutico , Amantadina/uso terapêutico , Clonazepam/uso terapêutico , Dopaminérgicos/uso terapêutico , Moduladores GABAérgicos/uso terapêutico , Ginkgo biloba , Humanos , Extratos Vegetais/uso terapêutico , Fatores de Risco , Discinesia Tardia/tratamento farmacológico , Tetrabenazina/análogos & derivados , Tetrabenazina/uso terapêutico , Valina/análogos & derivados , Valina/uso terapêuticoRESUMO
AIMS: Crigler-Najjar syndrome (CN) type II is a congenital disease with unconjugated hyperbilirubinemia due to a deficiency of uridine 5'-diphospho-glucuronosyltransferase 1A1. Since the currently proposed treatment with phenobarbital is associated with adverse reactions, we investigated the effect of hypericum extract. METHODS: Repetitive determination of total serum bilirubin in a female with CN type II before, during and after daily treatment with 900 mg hypericum extract on two occasions for 8 weeks. Confirmation of the enzyme-inducing effect of hypericum using the cytochrome P450 3A4 probe drug i.v. midazolam. RESULTS: Hypericum reduced midazolam exposure by 42% and the total serum bilirubin concentration by 30 to 35%. CONCLUSIONS: Hypericum extract is a potential alternative to phenobarbital in patients with CN type II.
Assuntos
Síndrome de Crigler-Najjar/tratamento farmacológico , Citocromo P-450 CYP3A/metabolismo , Hiperbilirrubinemia/tratamento farmacológico , Extratos Vegetais/uso terapêutico , Adulto , Área Sob a Curva , Bilirrubina/sangue , Síndrome de Crigler-Najjar/genética , Citocromo P-450 CYP3A/biossíntese , Indução Enzimática/efeitos dos fármacos , Feminino , Moduladores GABAérgicos/farmacocinética , Moduladores GABAérgicos/uso terapêutico , Glucuronosiltransferase/genética , Humanos , Hypericum , Midazolam/administração & dosagem , Midazolam/farmacocinética , Fenobarbital/uso terapêutico , Extratos Vegetais/administração & dosagem , Receptor de Pregnano X , Receptores de Esteroides/metabolismo , Adulto JovemRESUMO
OBJECTIVES: Use of anxiolytics-hypnotics, including benzodiazepines and "z" hypnotics, is a public health concern. This study aimed to investigate the trends in prevalence of anxiolytic-hypnotic drug use and polypharmacy (simultaneous use of two or more anxiolytics-hypnotics) in Taiwan. METHODS: A dynamic sample of one million individuals who were randomly selected from the National Health Insurance database was used to detect populationwide trends in the use of anxiolytics-hypnotics in Taiwan between 2002 and 2009. The analyses included drugs that are administered orally, intravenously, or intramuscularly as well as single or compound drugs. The authors identified the number of individuals who used the drugs, the sum of days of reported drug use for all individuals (person-days), and the distribution of anxiolytic-hypnotic polypharmacy for all claims for ambulatory, pharmacy, and hospital care. RESULTS: Annual prevalence of any anxiolytic-hypnotic use in Taiwan was higher than 20%. The number of person-days greatly increased from 2002 (4.0%) to 2009 (6.6%). The increases in use between 2002 and 2009 were greatest for clonazepam (prevalence, 7% versus 1.8%; person-days, .2% versus .6%) and zolpidem (prevalence, 2.4% versus 4.2%; person-days, .5% versus 1.5%). Polypharmacy accounted for almost 70% of all person-days of anxiolytic-hypnotic use. CONCLUSIONS: This nationwide, population-based survey presents real-world epidemiological evidence about anxiolytic-hypnotic use. The adverse effects of the long-term use of anxiolytics-hypnotics have been established, and unnecessary use of these drugs, particularly in polypharmacy regimens, should be avoided.
Assuntos
Ansiolíticos/uso terapêutico , Benzodiazepinas/uso terapêutico , Hipnóticos e Sedativos/uso terapêutico , Sistema de Registros/estatística & dados numéricos , Clordiazepóxido/uso terapêutico , Clonazepam/uso terapêutico , Estazolam/uso terapêutico , Moduladores GABAérgicos/uso terapêutico , Humanos , Programas Nacionais de Saúde/estatística & dados numéricos , Polimedicação , Medicamentos sob Prescrição/uso terapêutico , Piridinas/uso terapêutico , Taiwan/epidemiologia , Fatores de Tempo , ZolpidemRESUMO
Down syndrome (DS) is associated with neurological complications, including cognitive deficits that lead to impairment in intellectual functioning. Increased GABA-mediated inhibition has been proposed as a mechanism underlying deficient cognition in the Ts65Dn (TS) mouse model of DS. We show that chronic treatment of these mice with RO4938581 (3-bromo-10-(difluoromethyl)-9H-benzo[f]imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]diazepine), a selective GABA(A) α5 negative allosteric modulator (NAM), rescued their deficits in spatial learning and memory, hippocampal synaptic plasticity, and adult neurogenesis. We also show that RO4938581 normalized the high density of GABAergic synapse markers in the molecular layer of the hippocampus of TS mice. In addition, RO4938581 treatment suppressed the hyperactivity observed in TS mice without inducing anxiety or altering their motor abilities. These data demonstrate that reducing GABAergic inhibition with RO4938581 can reverse functional and neuromorphological deficits of TS mice by facilitating brain plasticity and support the potential therapeutic use of selective GABA(A) α5 NAMs to treat cognitive dysfunction in DS.
Assuntos
Síndrome de Down/complicações , Síndrome de Down/patologia , Hipocampo/patologia , Deficiências da Aprendizagem/tratamento farmacológico , Neurônios/fisiologia , Receptores de GABA-A/metabolismo , Estimulação Acústica , Análise de Variância , Animais , Benzodiazepinas/farmacologia , Benzodiazepinas/uso terapêutico , Biofísica , Proteínas de Transporte/metabolismo , Contagem de Células , Proliferação de Células/efeitos dos fármacos , Sinais (Psicologia) , Modelos Animais de Doenças , Síndrome de Down/tratamento farmacológico , Estimulação Elétrica , Potenciais Pós-Sinápticos Excitadores/efeitos dos fármacos , Potenciais Pós-Sinápticos Excitadores/genética , Comportamento Exploratório/efeitos dos fármacos , Moduladores GABAérgicos/farmacologia , Moduladores GABAérgicos/uso terapêutico , Glutamato Descarboxilase/metabolismo , Hipocampo/efeitos dos fármacos , Hipercinese/tratamento farmacológico , Hipercinese/etiologia , Imidazóis/farmacologia , Imidazóis/uso terapêutico , Antígeno Ki-67 , Deficiências da Aprendizagem/etiologia , Potenciação de Longa Duração/efeitos dos fármacos , Potenciação de Longa Duração/genética , Masculino , Aprendizagem em Labirinto/efeitos dos fármacos , Proteínas de Membrana/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Neurogênese/efeitos dos fármacos , Neurogênese/genética , Neurônios/efeitos dos fármacos , Ligação Proteica/efeitos dos fármacos , Ligação Proteica/genética , Desempenho Psicomotor/efeitos dos fármacos , Tempo de Reação/efeitos dos fármacos , Reflexo/efeitos dos fármacos , Reflexo/genética , Reflexo de Sobressalto/efeitos dos fármacos , Teste de Desempenho do Rota-Rod , Convulsões/etiologia , Filtro Sensorial/efeitos dos fármacos , Trítio/farmacocinética , Proteínas Vesiculares de Transporte de Aminoácidos Inibidores/metabolismoRESUMO
Gamma aminobutyric acid (GABA)-mediated synapses and the oscillations they orchestrate are altered in autism. GABA-acting benzodiazepines exert in some patients with autism paradoxical effects, raising the possibility that like in epilepsies, GABA excites neurons because of elevated intracellular concentrations of chloride. Following a successful pilot study,(1) we have now performed a double-blind clinical trial using the diuretic, chloride-importer antagonist bumetanide that reduces intracellular chloride reinforcing GABAergic inhibition. Sixty children with autism or Asperger syndrome (3-11 years old) received for 3 months placebo or bumetanide (1 mg daily), followed by 1-month wash out. Determination of the severity of autism was made with video films at day 0 (D0) and D90 by blind, independent evaluators. Bumetanide reduced significantly the Childhood Autism Rating Scale (CARS) (D90-D0; P<0.004 treated vs placebo), Clinical Global Impressions (P<0.017 treated vs placebo) and Autism Diagnostic Observation Schedule values when the most severe cases (CARS values above the mean ± s.d.; n=9) were removed (Wilcoxon test: P-value=0.031; Student's t-test: P-value=0.017). Side effects were restricted to an occasional mild hypokalaemia (3.0-3.5 mM l(-1) K(+)) that was treated with supplemental potassium. In a companion study, chronic bumetanide treatment significantly improved accuracy in facial emotional labelling, and increased brain activation in areas involved in social and emotional perception (Hadjikhani et al., submitted). Therefore, bumetanide is a promising novel therapeutic agent to treat autism. Larger trials are warranted to better determine the population best suited for this treatment.
Assuntos
Transtorno Autístico/tratamento farmacológico , Bumetanida/uso terapêutico , Moduladores GABAérgicos/uso terapêutico , Síndrome de Asperger/tratamento farmacológico , Transtorno Autístico/diagnóstico , Transtorno Autístico/psicologia , Criança , Pré-Escolar , Método Duplo-Cego , Feminino , Humanos , Masculino , Índice de Gravidade de Doença , Resultado do TratamentoAssuntos
Anticonvulsivantes/uso terapêutico , Bromazepam/efeitos adversos , Flumazenil/uso terapêutico , Moduladores GABAérgicos/uso terapêutico , Agonistas de Receptores de GABA-A/uso terapêutico , Piridinas/efeitos adversos , Transtornos Relacionados ao Uso de Substâncias/tratamento farmacológico , Ácido Valproico/uso terapêutico , Adulto , Bromazepam/administração & dosagem , Feminino , Humanos , Piridinas/administração & dosagem , ZolpidemRESUMO
Burning mouth syndrome (BMS) is defined as a chronic pain condition, characterized symptomatically by a generalized or localized burning sensation in the oral cavity. Various drugs have been used in attempting to treat BMS, but there is insufficient evidence to show the effect of any effective treatment. The aim of this review was to assess the effectiveness of therapies for BMS. Randomized controlled trials (RCTs) enrolling patients with a diagnosis of BMS were identified by searching Pubmed and Scoppus databases. The methodological quality of included studies was assessed on the basis of the method of allocation concealment, blindness of the study, loss of participants, size sample, and outcome concealment. A total of 12 relevant articles were analyzed. Therapies that used capsaicin, alpha-lipoic acid (ALA), and clonazepam were those that showed more reduction in symptoms of BMS. However, many studies of therapeutic interventions in BMS lack consistency in their results, because they use in their methodology, sample and a relatively short time of therapy and often do not provide a follow-up of patients treated. Thus, future studies are required to establish the treatment for patients suffering from this chronic and painful syndrome.
Assuntos
Síndrome da Ardência Bucal/tratamento farmacológico , Odontologia Baseada em Evidências , Antioxidantes/uso terapêutico , Capsaicina/uso terapêutico , Clonazepam/uso terapêutico , Moduladores GABAérgicos/uso terapêutico , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto/normas , Fármacos do Sistema Sensorial/uso terapêutico , Ácido Tióctico/uso terapêuticoRESUMO
Status epilepticus is a common neurological emergency in childhood and associated with significant morbidity and mortality. Status epilepticus (SE) has been defined as continuous seizure activity lasting more than 30 min or 2 or more seizures in this duration without gaining consciousness between them. However, the operational definition has brought the time down to 5 min. Management can be broadly divided into initial stabilization, seizure termination, and evaluation and treatment of the underlying cause. Diagnostic evaluation and seizure control should be achieved simultaneously to improve outcome. Seizure termination is achieved by pharmacotherapy. Benzodiazepines are the first line drugs for SE. Commonly used drugs include lorazepam, diazepam, and midazolam. In children without an IV access, buccal or nasal midazolam or rectal diazepam can be used. Phenytoin as a second line agent is usually indicated when seizure is not controlled after one or more doses of benzodiazepines. If the seizures continue to persist, valproate, phenobarbitone or levetiracetam is indicated. Midazolam infusion is useful in refractory status epilepticus. Thiopentone, propofol or high dose phenobarbitone are considered for treatment of refractory status epilepticus. Prolonged SE is associated with higher morbidity and mortality. Long term neurological sequelae include epilepsy, behavioural problems, cognitive decline, and focal neurologic deficits.